Nektar Therapeutics (NKTR) Tops Q3 EPS by 17c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/7/2026

1. MRVL
2. ZS
3. PENG
4. STZ
5. SKYD
6. HALO
7. BBIO
8. SPY
9. RCKT
10. CRWV

Go back to Nektar Therapeutics (NKTR) Tops Q3 EPS by 17c

Nektar Therapeutics Reports Financial Results for the Third Quarter of 2019

November 6, 2019 4:03 PM EST

SAN FRANCISCO, Nov. 6, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the third quarter ended September 30, 2019.

Cash and investments in marketable securities at September 30, 2019 were approximately $1.7 billion as compared to $1.9 billion at December 31, 2018.

"We continue to make steady progress with our diverse portfolio of immuno-oncology and immunology programs," said Howard W. Robin, President and CEO of Nektar. "With our partner Bristol-Myers Squibb, we are conducting registrational trials evaluating the combination of bempegaldesleukin with nivolumab in melanoma, urothelial cancer and renal cell carcinoma. We are... More